High dialysate calcium may improve the efficacy of calcimimetic treatment in hemodialysis patients with severe secondary hyperparathyroidism [1] (multiple letters)

Kidney International

Volumn 67, Issue 5, 2005, Pages 2065-2066

  Touam, Malik ^b   Menoyo, Victorio ^b   Attaf, David ^b   Thebaud, Henri Emile ^b   Drüeke, Tilman B ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; CALCIMIMETIC AGENT; CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; SEVELAMER; VITAMIN D;

CLINICAL TRIAL; DIALYSATE LEVEL; DISEASE CONTROL; DOSE RESPONSE; DRUG EFFICACY; HEMODIALYSIS; HUMAN; LETTER; MOLECULAR WEIGHT; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; REDUCTION; SECONDARY HYPERPARATHYROIDISM;

EID: 17744386939     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.310_1.x     Document Type: Letter

References (4)

1. L.A. Szczech The impact of calcimimetic agents on the use of different classes of phosphate binders: Results of recent clinical trials Kidney Int 2004 S46 48
2. G.A. Block K.J. Martin A.L. De FRANCISCO Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis N Engl J Med 350 2004 1516 1525
3. L.D. Quarles D.J. Sherrard S. Adler The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease J Am Soc Nephrol 14 2003 575 583
4. J.S. Lindberg S.M. Moe W.G. Goodman The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism Kidney Int 63 2003 248 254